Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7293583 in Metastatic Melanoma
NCT04551352Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of RO7293583 in melanoma, cutaneous melanoma (CM), Uveal melanoma (UM) and 1 more (2 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities and Adverse Events up to 14 months. Started Oct 2020; status: completed.
02
Drugs
RO7293583
03
Conditions
melanomacutaneous melanoma (CM)Uveal melanoma (UM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04551352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551352.